Signum Biosciences Receives $3.0M Phase IIB SBIR Grant for the Development of SIG1451, A Novel Atopic Dermatitis Therapeutic

Signum Biosciences, Inc. announces today that the National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a Small Business Innovation Research (SBIR) Phase IIB grant totaling $3.0 million over 3 years for the development of a novel topical non-steroidal anti-inflammatory drug candidate for atopic dermatitis (AD).  

Utilizing the funding provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) via the preceding Phase II grant, Signum identified SIG1451 from its isoprenylcysteine (IPC) technology platform as its lead drug candidate for AD. This Phase IIB funding will be used to take SIG1451 through IND-enabling safety/toxicology studies and into the clinic, where Post-IND clinical, chemistry and formulation work will also be performed.

Dr. Eduardo Pérez, CSO stated, “Over the past decade we have built a robust medicinal chemistry and R&D team to mine our IPC library for new therapeutics. Building on the experience and momentum provided by SIG990/DMT210, we believe SIG1451 will provide an important additional, and potentially better, therapeutic option for those suffering from AD.” 

Full Press Release

SIG-990 aka ( DMT210) has entered into a Phase 2 Acne Rosacea Study conducted by our Dermata Therapeutics, LLC

Exciting news regarding our licensee, Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, announces dosing the first patient with its lead compound DMT210, in a Phase 2 acne rosacea study. DMT210, (formerly Signum's SIG-990 molecule) is a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne rosacea.   Full Press Release

SIG-1191: an anti-inflammatory molecule that increases the expression of the aquaglyceroporin, aquaporin-3, in human keratinocytes

Isoprenylcysteine (IPC) small molecules were discovered as signal transduction modulating compounds ~25 years ago. More recently, IPC molecules have demonstrated antioxidant and anti-inflammatory properties in a variety of dermal cells as well as antimicrobial activity, representing a novel class of compounds to ameliorate skin conditions and disease. Here, we demonstrate a new IPC compound, N-acetylglutaminoyl-S-farnesyl-l-cysteine (SIG-1191), which inhibits UVB-induced inflammation blocking pro-inflammatory cytokine interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) production. To investigate further the previously reported hydrating potential of IPC compounds, SIG-1191 was tested for its ability to modulate aquaporin expression. Specifically, aquaporin 3 (AQP3) the most abundant aquaporin found in skin has been reported to play a key role in skin hydration, elasticity and barrier repair. Results show here for the first time that SIG-1191 increases AQP3 expression in both cultured normal human epidermal keratinocytes as well as when applied topically in a three-dimensional (3D) reconstructed human skin equivalent. Additionally, SIG-1191 dose dependently increased AQP3 protein levels, as determined by specific antibody staining, in the epidermis of the 3D skin equivalents. To begin to elucidate which signaling pathways SIG-1191 may be modulating to increase AQP3 levels, we used several pharmacological pathway inhibitors and determined that AQP3 expression is mediated by the Mitogen-activated protein kinase/Extracellular signal-regulated kinase kinase (MEK) pathway. Altogether, these data suggest SIG-1191 represents a new IPC derivative with anti-inflammatory activity that may also promote increased skin hydration based on its ability to increase AQP3 levels.

Here is the link to the full article. SIG-1191): an anti-inflammatory molecule that increases the expression of the aquaglyceroporin, aquaporin-3, in human keratinocytes


Signum's lead Rx molecule SIG990 (DMT210) for Rosacea, it reduces redness and bumps in rosacea subjects.

Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients. Click here to see Dermata's Press release. DMT210 is an IPC molecule (SIG990) that Signum licensed to Dermata to develop as a treatment for Rosacea.

"The safety results are supported with the findings from our pre-clinical data that DMT210 has a favorable safety profile, which remains extremely important to patients and dermatologists for dermal products," states Gerald Proehl, President and CEO of Dermata. "We are also very excited to see that DMT210 reduced erythema and lesion counts in only a 28-day study, giving us further confidence that we will see even greater reductions in our 90-day study."

We have partnered with Dermata Therapeutics, LLC , a private specialty pharmaceutical company developing innovative prescription drugs for dermatological conditions. We have out-Licensed SIG990 to Dermata Therapeutics for the topical treatment of rosacea. SIG990 is a novel, first-in-class anti-inflammatory compound which has the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The Investigational New Drug (IND) application for SIG990 has been cleared by the U.S. Food and Drug Administration (FDA) and SIG990 is thus ready to be evaluated in subjects. Dermata has obtained an exclusive worldwide license to SIG990 and is responsible for the clinical development of the product.

With the completion of this study, Dermata plans to move into two Phase 2 studies in Acne Rosacea and Atopic Dermatitis, both expected to start later this year.

Here is a link to learn more about SIG990.

Signum Dermalogix's Pipeline